1.Propylthiouracil Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Graves' Disease.
Bo Mi PARK ; Sook Jung YUN ; Seong Jin KIM ; Seung Chul LEE ; Young Ho WON ; Jee Bum LEE
Korean Journal of Dermatology 2012;50(5):479-480
No abstract available.
Eosinophilia
;
Graves Disease
;
Propylthiouracil
2.A Case of Propylthiouracil-Induced Lupus.
Jaechun LEE ; Bin YOO ; Yun Jeong LIM ; Seong Ho KIM ; Mikyung LIM ; You Sook CHO ; Young Kee SHONG ; Hee Bom MOON
The Journal of the Korean Rheumatism Association 1999;6(1):75-78
Propylthiouracil(PTU) is one of lupus-inducing drugs, though rarely reported. We report a case of PTU-induced lupus, with the review of of previous literatures. Lupus-like symptoms in a 28year-old female patient, who had been suffering from relapsed Graves' disease, were presented during PTU therapy. The results of antinuclear antibody and anti-histone antibody were positive. After symptomatic reatment and discontinuation of PTU, all of the symptoms and the abnormalities in laboratory tests disappeared, which suggested drug-induced lupus.
Antibodies, Antinuclear
;
Female
;
Graves Disease
;
Humans
;
Propylthiouracil
5.A Case of p-ANCA-Positive Propylthiouracil-Induced Pyoderma Gangrenosum.
Jong Won SEO ; Hyun Ho SON ; Joon Hee CHOI ; Sook Kyung LEE
Annals of Dermatology 2010;22(1):48-50
Propylthiouracil is a common medication used in patients with hyperthyroidism; it can cause perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) in some patients with Graves' disease. This antibody has been associated with various forms of vasculitis and neutrophilic dermatosis. Herein, we report a patient who presented with cutaneous manifestations of pyoderma gangrenosum with simultaneous development of p-ANCAs during PTU therapy for Graves' disease.
Antibodies, Antineutrophil Cytoplasmic
;
Graves Disease
;
Humans
;
Neutrophils
;
Propylthiouracil
;
Pyoderma
;
Pyoderma Gangrenosum
;
Skin Diseases
;
Vasculitis
6.A Case of Propylthiouracil Induced Diffuse Pulmonary Hemorrhage.
Sung Yong LEE ; Jin Yong JUNG ; Kyoung Ju LEE ; Seung Hyeun LEE ; Se Joong KIM ; Eun Joo LEE ; Gyu Young HUR ; Hae Chul JUNG ; Sang Yeub LEE ; Je Hyeong KIM ; Chol SHIN ; Jae Jeong SHIM ; Kwang Ho IN ; Kyung Ho KANG ; Se Hwa YOO
Tuberculosis and Respiratory Diseases 2005;58(1):78-82
Propylthiouracil(PUT) is a drug which used at Grave's disease. But PTU has recently been observed to associated with antineutrophil cytoplasmic antibody(ANCA)-positive vasculitis resulting in, infrequently, diffuse alveolar he?morrhage. We report the case of a patient who developed diffuse pulmonary hemorrhage after she had been taking PTU for two years. She had received a diagnosis of Grave's disease at two years ago. The serologic study was positive for ANCA with myeloperoxidase(MPO) specificity. Bronchoalveloar lavage(BAL) fluid analysis revealed hemosiderin- laden macrophages. Such findings suggested propylthiouracil?induced dffuse pulmonary hemorrhage associated with antineutrophil cytoplasmic antibody. To our knowledge, this represents the first documentation in a case of PTU-induced diffuse pulmonary hemorrhage in Korea.
Antibodies, Antineutrophil Cytoplasmic
;
Cytoplasm
;
Diagnosis
;
Hemorrhage*
;
Humans
;
Korea
;
Macrophages
;
Propylthiouracil*
;
Vasculitis
7.Hepatic Injury during Treatment with Antithyroid Drugs in Patients with Hyperthyroidism.
Ki Young LEE ; Yun Jeong LEE ; Soon Hong HONG ; Sung Kwoen JUNG ; Hwa Eun LEE ; Chan Jong SEO ; Yon Sil JUNG ; Sung Kwang LEE ; Hong Kyu KIM ; Hye Young PARK ; Moon Ho KANG
Journal of Korean Society of Endocrinology 2000;15(4-5):554-560
BACKGROUND: Propylthiouracil (PIV) and methimazole (MMI) were widely used for the treatment of hyperthyroidism. Hepatic injury caused by these agents is a rare but serious complication. This study is to investigate the clinical features of hepatotoxicity from antithyroid drugs. METHODS: We reviewed 17 cases of hepatic injury during treatment with antithyroid drugs in patients with hyperthyroidism. Included were 6 cases we experienced and 11 cases reported in Korean literature from 1986 to 1999. We analyzed the clinical features of hepatic injury. RESULTS: Of 17 cases of hepatic injury, 12 were PTU cases and 5 MMI cases. The mean age of PTU cases was 40 years with 6/12 patients over 40 years old and 2/5 MMI cases were over 40 years old. The dose of PTU was 300 mg/d or more in 10/12 cases (83%) and the dose of MMI was 30 mg/d in 3/5 cases (60%). The hepatic injury occurred within 3 months in 8/12 PTU cases (67%) and within 2 months in 4/5 MMI cases (80%). The duration of hepatic injury tended to be longer in MMI cases than in PTV cases (median; 80 vs 41 days, p=0.102). In PTU cases, the duration of hepatic injury was correlated with the duration of drug use before hepatic injury (p<0.05). All of 8 biopsied cases who took PTU had predominantly hepatocellular necrosis. Two biopsied cases who took MMI had cholestatic jaundice and nonspecific abnormality, respectively. Biochemical findings of all MMI cases were compatible with cholestatic jaundice. As to the treatment of hyperthyroidism after hepatic injury, 4/12 PTU cases were treated with RAI therapy, 5 with MMI and one with surgery, and treatment was unknown in two. On the other hand 3/5 MMI cases interestingly entered into spontaneous remission after hepatic injury and 2/5 had RAI therapy. Hepatic dysfunction recurred in each one whom treatment by changing to MMI or PTU was tried on. CONCLUSION: Most of hepatic injury during treatment with antithyroid drugs developed within two to three months of drug use. The hepatic injury related to PTU was mainly cytotoxic whereas that related to MMI was cholestatic. Since there is a cross-reaction between PTU and MMI in hepatotoxicity, RAI therapy or operation shoud be considered as an alternative treatment of hyperthyroidism after hepatic injury.
Adult
;
Antithyroid Agents*
;
Hand
;
Humans
;
Hyperthyroidism*
;
Jaundice, Obstructive
;
Methimazole
;
Necrosis
;
Propylthiouracil
;
Remission, Spontaneous
8.Incidence & Prevalence of Hyperthyroidism and Preference for Therapeutic Modalities in Korea.
Gi Hyeon SEO ; Sun Wook KIM ; Jae Hoon CHUNG
Journal of Korean Thyroid Association 2013;6(1):56-63
BACKGROUND AND OBJECTIVES: The incidence and prevalence of hyperthyroidism has been reported to be 0.2-0.9/1000 population/year and 5-10/1000 population in foreign countries, respectively. However, there has been no nationwide survey to evaluate them in Korea. Therefore, this study was conducted to investigate the incidence and prevalence of hyperthyroidism in Korea using medicare claims data provided by the Health Insurance Review and Assessment Service. Preference for its therapeutic modalities and its change were also analyzed. MATERIALS AND METHODS: This study was performed in 308,584 (men 86,460, women 222,124) Korean patients with hyperthyroidism treated from January 2006 to June 2012. Patients with past history of hyperthyroidism were not included. RESULTS: The incidence of hyperthyroidism was 0.72/1000 population/year (men 0.40, women 1.03), and its prevalence was 3.40/1000 population (men 2.09, women 4.70) in Korea. Its peak prevalence was detected between 45 and 49 years of age. Among 177,487 patients with hyperthyroidism treated from 2007 to 2011, anti-thyroid drugs were prescribed in 97.9%, and radioiodine therapy and surgery were finally performed in 8.2% and 0.9%, respectively. The prescription of propylthiouracil (PTU) has been reduced from 63.3% in 2007 to 42.9% in 2011, but the use of methimazole (MMI) increased from 33.9% in 2007 to 54.8% in 2011. Primary physicians preferred PTU to MMI, but physicians in general hospitals preferred MMI to PTU. CONCLUSION: This is the first nationwide report to investigate the incidence and prevalence of hyperthyroidism in Korea.
Female
;
Hospitals, General
;
Humans
;
Hyperthyroidism
;
Incidence
;
Insurance, Health
;
Korea
;
Medicare
;
Methimazole
;
Prescriptions
;
Prevalence
;
Propylthiouracil
9.Two Cases of Aplastic Anemia Following Propylthiouracil.
Hong Seung KIM ; Choon Hee CHUNG ; Hee Sun KIM ; Mi Duk LEE ; Young Hak SHIM ; Soon Won HONG
Journal of Korean Society of Endocrinology 1998;13(2):258-263
Aplastic anemia is characterized by a failure of blood cell production resulting in varying degrees of pancytopenia with a markedly hypocellular bone marrow. Most cases of aplastic anemia are acquired, but the disease may also occur as the result of inherited abnormalities. In 50-65% of cases, however, the etiology is unknown. For acquired forms of aplastic anemia, a variety of causative factors, including radiation, viruses, chemicals and drugs, have been implicated. Antithyroid drugs(Carbimazole, Methimazole, Propylthiouracil) are usually listed among agents associated with the development of agranulocytosis, but aplastic anemia rarely follows their use. The first case of aplastic anemia followmg propylthiouracil was reported by Marte~lo et al. in 1967 and the second case was by Aksoy and Erdem in 1968. Recently, we experienced two cases of aplastic anemia following propylthiouracil therapy due to Graves disease, so we report here these cases with literature review.
Agranulocytosis
;
Anemia, Aplastic*
;
Blood Cells
;
Bone Marrow
;
Graves Disease
;
Methimazole
;
Pancytopenia
;
Propylthiouracil*
10.A case of propylthiouracil-induced hepatitis with agranulocytosis.
Jae Kyun LEE ; Hong Ja KIM ; Hwa Eun OH
Korean Journal of Medicine 2001;61(1):50-52
Hyperthyroidism is a common condition which is initially managed with an antithyroid drug, either propylthiouracil or methimazole. Adverse reactions occur in 1-5% of patients taking antithyroid medications, most commonly transient, benign leukopenia and skin rash. Agranulocytosis and liver dysfunction are reactions which occur infrequently. Severe hepatic toxicity combined with agranulocytosis has been known as rare complication. Experimental studies have demonstrated that immunological mechanisms play an important role. While most patients are completely recovered after stop of medication, some patients can show grave prognosis. We report a case of propylthiouracil induced hepatitis with agranulocytosis.
Agranulocytosis*
;
Exanthema
;
Hepatitis*
;
Humans
;
Hyperthyroidism
;
Leukopenia
;
Liver Diseases
;
Methimazole
;
Prognosis
;
Propylthiouracil